Inactive Instrument

Press Releases Concert Pharmaceuticals, Inc.

Equities

CNCE

US2060221056

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Alopecia Areata Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)	23-09-27	AQ
SUN PHARMA - LATE-BREAKING PHASE 3 DATA AT AAD 2023 SHOW ORAL INVESTIGATIONAL MEDICINE DEURUXOLITINIB SIGNIFICANTLY IMPROVED SCALP HAIR REGROWTH IN ALOPECIA AREATA	23-03-20	AQ
CONCERT PHARMACEUTICALS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	23-03-06	AQ
Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata	23-02-15	BU
CONCERT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Concert Pharmaceuticals, Inc. - CNCE	23-01-20	BU
CONCERT PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	23-01-19	AQ
Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata	23-01-19	BU
Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research	22-11-21	BU
Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference	22-11-09	BU
CONCERT PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-11-07	AQ
Concert: Q3 Earnings Snapshot	22-11-07	AQ
Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results	22-11-07	BU
Concert Pharmaceuticals to Report Third Quarter 2022 Results on November 7, 2022	22-10-31	BU
CONCERT PHARMACEUTICALS ANNOUNCES PRESENTATION OF CTP-543 THRIVE-AA1 PHASE 3 DATA IN ALOPECIA AREATA DURING LATE BREAKING SESSION AT EADV CONGRESS	22-09-12	AQ
Concert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 Phase 3 Data in Alopecia Areata During Late Breaking Session at EADV Congress	22-09-10	BU
Concert Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference	22-09-06	BU
Bridges and Landmarks Across the USA Will Illuminate Blue Throughout the Month of September for Alopecia Areata	22-09-01	BU
CONCERT PHARMACEUTICALS, INC. : Other Events (form 8-K)	22-08-22	AQ
Concert Pharmaceuticals Announces That Results From CTP-543 THRIVE‑AA1 Phase 3 Trial in Patients With Alopecia Areata Selected for Late Breaking Presentation at EADV Congress	22-08-22	BU
Concert Pharmaceuticals Announces Exercise of Warrants Under Existing Financing Arrangement	22-08-22	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Concert Pharmaceuticals, Inc.

Equities

CNCE

US2060221056

Press Releases

Filters